Vaxcyte, Inc.
NASDAQPCVX arrives at its August 6 earnings release in an unusual position for a clinical-stage biotech: short sellers have been cutting exposure, not adding to it, even as the stock trades well below where analysts think it belongs. The short-side retreat is the clearest signal in the pre-print positioning. Short interest has fallen roughly 19% from its mid-July peak — dropping from…
Snapshot as of 6 Aug 2026
PCVX arrives at its August 6 earnings release in an unusual position for a clinical-stage biotech: short sellers have been cutting exposure, not adding to it, even as the stock trades well below where analysts think it…
PCVX reports Q1 2026 results after the close today, with one of the more committed short positions in mid-cap biotech setting the backdrop. Short sellers hold roughly 10.8% of the free float — up 8.7% over the past…
PCVX reported Q1 2026 results after the close on May 6 — an EPS of -$2.30 against a -$1.82 consensus estimate — capping a week in which the stock already slid 5.3% to $55.64 and short interest climbed to its highest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PCVX — free to start on ORTEX.
Sign up for free →Open PCVX on ORTEX